Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Albiruni R A, Razak"'
Autor:
Scott C. Lien, Dalam Ly, S. Y. Cindy Yang, Ben X. Wang, Derek L. Clouthier, Michael St. Paul, Ramy Gadalla, Babak Noamani, Carlos R. Garcia-Batres, Sarah Boross-Harmer, Philippe L. Bedard, Trevor J. Pugh, Anna Spreafico, Naoto Hirano, Albiruni R. A. Razak, Pamela S. Ohashi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of i
Externí odkaz:
https://doaj.org/article/fd59752fa86742a8a6eab34aa0b37b3b
Autor:
Sofia Genta, Katherine Lajkosz, Noelle R. Yee, Pavlina Spiliopoulou, Alya Heirali, Aaron R. Hansen, Lillian L. Siu, Sam Saibil, Lee-Anne Stayner, Maryia Yanekina, Maxwell B. Sauder, Sareh Keshavarzi, Abdulazeez Salawu, Olga Vornicova, Marcus O. Butler, Philippe L. Bedard, Albiruni R. Abdul Razak, Robert Rottapel, Andrzej Chruscinski, Bryan Coburn, Anna Spreafico
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-13 (2023)
Abstract Background Immune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The mechanisms underlying irAEs development are mostly unknown and might involve multiple immune effecto
Externí odkaz:
https://doaj.org/article/b47044a90bde498cb63139e5570ed22f
Autor:
Alberto Hernando-Calvo, Paul Nguyen, Philippe L. Bedard, Kelvin K.W. Chan, Ramy R. Saleh, Deirdre Weymann, Celeste Yu, Eitan Amir, Dean A. Regier, Bishal Gyawali, Danielle Kain, Brooke Wilson, Craig C. Earle, Nicole Mittmann, Albiruni R. Abdul Razak, Wanrudee Isaranuwatchai, Peter Sabatini, Anna Spreafico, Tracy L. Stockley, Trevor J. Pugh, Christine Williams, Lillian L. Siu, Timothy P. Hanna
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102443- (2024)
Summary: Background: To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival (OS), cl
Externí odkaz:
https://doaj.org/article/19ab2f66fed24a75a727e76111c21e84
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
Autor:
Nathaniel D. Anderson, Yael Babichev, Fabio Fuligni, Federico Comitani, Mehdi Layeghifard, Rosemarie E. Venier, Stefan C. Dentro, Anant Maheshwari, Sheena Guram, Claire Wunker, J. Drew Thompson, Kyoko E. Yuki, Huayun Hou, Matthew Zatzman, Nicholas Light, Marcus Q. Bernardini, Jay S. Wunder, Irene L. Andrulis, Peter Ferguson, Albiruni R. Abdul Razak, Carol J. Swallow, James J. Dowling, Rima S. Al-Awar, Richard Marcellus, Marjan Rouzbahman, Moritz Gerstung, Daniel Durocher, Ludmil B. Alexandrov, Brendan C. Dickson, Rebecca A. Gladdy, Adam Shlien
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Heterogeneity in leiomyosarcomas (LMS) makes treatment of the disease challenging. Here the authors analyze LMS heterogeneity and molecular LMS subtypes using genomics and transcriptomics, finding origins in distinct lineages and associations with su
Externí odkaz:
https://doaj.org/article/c08bf52065ac4dcd90672db6a2810128
Autor:
Brian A Van Tine MD, PhD, Anders Krarup-Hansen MD, PhD, Lisa M Hess PhD, Albiruni R Abdul Razak MD, Victoria Soldatenkova MSc, Jennifer Wright MD, Se Hoon Park MD
Publikováno v:
Rare Tumors, Vol 14 (2022)
Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported
Externí odkaz:
https://doaj.org/article/eeb8b1752f264cfaa1ea44fc9c3eb400
Autor:
Kari Ala‐Leppilampi, Natalie A. Baker, Chris McKillop, Marcus O. Butler, Lillian L. Siu, Anna Spreafico, Albiruni R. Abdul Razak, Anthony M. Joshua, David Hogg, Philippe L. Bedard, Natasha Leighl, Amit M. Oza, Janet A. Parsons, Aaron R. Hansen
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3015-3022 (2020)
Abstract Background Minimal qualitative data exist on the experiences of cancer patients treated with immune checkpoint inhibitors or costimulatory antibodies. Understanding the day to day experiences of patients being treated with immune checkpoint
Externí odkaz:
https://doaj.org/article/791284663301419f8555fe2acf46ac6b
Autor:
Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Nunez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren A. Chow, George D. Demetri, Mihaela Druta, Brian A. Van Tine, Stephan A. Grupp, Albiruni R. Abdul Razak, Breelyn Wilky, Malini Iyengar, Trupti Trivedi, Erin Van Winkle, Karen Chagin, Rafael Amado, Gwendolyn K. Binder, Samik Basu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated
Externí odkaz:
https://doaj.org/article/08dda14b5f1b4ef08600740b083a4b11
Autor:
Derek L. Clouthier, Scott C. Lien, S. Y. Cindy Yang, Linh T. Nguyen, Venkata S. K. Manem, Diana Gray, Michael Ryczko, Albiruni R. A. Razak, Jeremy Lewin, Stephanie Lheureux, Ilaria Colombo, Philippe L. Bedard, David Cescon, Anna Spreafico, Marcus O. Butler, Aaron R. Hansen, Raymond W. Jang, Sangeet Ghai, Ilan Weinreb, Valentin Sotov, Ramy Gadalla, Babak Noamani, Mengdi Guo, Sawako Elston, Amanda Giesler, Sevan Hakgor, Haiyan Jiang, Tracy McGaha, David G. Brooks, Benjamin Haibe-Kains, Trevor J. Pugh, Pamela S. Ohashi, Lillian L. Siu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce. INSPIRE is a phase
Externí odkaz:
https://doaj.org/article/31ba8dd2f028423db6db252c1c7723fb
Publikováno v:
Targeted Oncology. 17:665-674
Autor:
Nicolas Devaud, Olga Vornicova, Albiruni R. Abdul Razak, Korosh Khalili, Elizabeth G. Demicco, Cristina Mitric, Marcus Q. Bernardini, Rebecca A. Gladdy
Publikováno v:
Surgical Oncology Clinics of North America. 31:527-546